REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

Current tag:

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Prof. Andreas Busch January 2011. An unmasked account of decisions about investing into cancer stem cell research and the fate of regenerative medicine projects in Japan. Dr Busch summarises results and evaluates technology platforms like novel antibodies and wnt mechanisms. He voices his expectations from current key drug development partnerships, in particular with Oncomed and Micromet. Will these include companion diagnostics? To what extent does Bayer retain respective intellectual property rights? A comment on personalised medicine and cancer stem cells research pursued by Merck KGaA and others. What are prospects for classic oncology drugs?

Horizon Discovery: Mitigating risks and developing the U.S. business

Tasks ahead for Eric Rhodes, the new CTO

Roche Ethiopia: Build-up of an emerging market

Systems Biology: In search of good questions

Prof Walter Kolch on the approach taken by Systems Biology Ireland

B2Bioworld Stem Cell Insights Collection 2010:

Issues and Evaluation from Pharma Leaders

Dr Patrick Vallance, GSK:

Stem Cell Research Now and in the Future

No Mercy with Violators of Corporate Compliance

Dr Rüdiger Scheitza, Member of the Board Bayer CropScience, and Labour Director

If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

Lilly Ventures: Is it worth a dollar, or a million dollars?

Ed Torres, Managing Director of Lilly Ventures on the fund’s input to Eli Lilly’s business development

S. Edward Torres December 2010. What strategies is Lilly’s Venture Fund pursuing in the US and Latin America. Ed Torres, Managing Director of Lilly Ventures describes for B2Bioworld investment policies in biotechnology, medical technologies, and healthcare IT, as well as future plans. There will be a marked change with regard to the Fund’s approach in Europe. But what is at stake, when non-profit organisations have a major say? Moreover, what is the critical input to the parent company in developing its global business and filling up the pipeline. Includes a detailed overview on current investments as well as co-investors compiled by B2Bioworld.